The KLC1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, intended for loss-of-function analysis of the KLC1 gene. This product provides a heterogeneous pool of KLC1-disrupted cells, enabling functional studies of kinesin-1 motor complex-dependent processes without clonal selection artifacts. It serves as a versatile tool for investigating microtubule-based transport mechanisms in a cancer-relevant cellular context.
The A-549 host cell line, established from a 58-year-old Caucasian male with lung adenocarcinoma, exhibits epithelial morphology and is widely used for oncogenesis and drug response research. Its retention of alveolar type II pneumocyte features makes it an appropriate model for examining the relationship between intracellular trafficking defects and lung cancer biology.
KLC1 encodes kinesin light chain 1, a subunit that pairs with KIF5B heavy chain to form the kinesin-1 motor, which drives anterograde transport along microtubules. Its activity is regulated by upstream kinases including JNK and GSK3?? via phosphorylation, influencing cargo binding. KLC1 interacts with adaptor proteins JIP1, JIP3, and HAP1 to tether mitochondria, lysosomes, and other cargo. Downstream, KLC1-mediated transport is essential for mitochondrial distribution, lysosomal positioning, mitotic spindle assembly, cytokinesis, and cell migration, integrating signals from MAPK pathways.
In A-549 lung adenocarcinoma cells, KLC1 knockout disrupts intracellular trafficking, potentially impairing mitotic fidelity, organelle homeostasis, and migratory capacity. Because enhanced migration and invasion are hallmarks of metastatic non-small cell lung cancer, this model enables dissection of kinesin-1??s role in cancer aggressiveness, including possible defects in pro-invasive factor delivery or energy metabolism. The disrupted transport network provides a platform to study tumor progression mechanisms.
Key applications include live-cell imaging of organelle transport, immunofluorescence microscopy for mitochondrial and lysosomal distribution, Boyden chamber migration and invasion assays, co-immunoprecipitation of motor complex components, and Western blotting for target validation. Functional assays such as proliferation and cell cycle analysis, together with transcriptomic profiling, can uncover broader impacts of KLC1 loss. This polyclonal knockout cell population supports functional genomics and drug target validation for anti-metastatic therapies. For additional information and ordering, please contact Ascent Research.
